3 completed, 2 unknown. 4 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow FCN-437c: new trials by email Literature Review of FCN-437c trials Research Report on FCN-437c
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency FCN-437c capsule - Hepatic Insufficiency | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 24 | 2023-09-04 | 2024-11-12 |
| Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects Low dose group, High dose group - Advanced Breast Cancer | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 18 | 2022-11-11 | 2024-03-04 |
| This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. FCN-437c, Letrozole or anastrozole, Goserelin acetate, Placebo, Letrozole or anastrozole, Goserelin acetate - Advanced Breast Cancer, Female Breast Cancer | Phase 3 | Unknown | Ahon Pharmaceutical Co., Ltd. | 434 | 2022-03-02 | 2022-07-06 |
| Study of FCN-437c in Patients With Advanced Solid Tumors FCN-437 - Solid Tumor, Adult | Phase 1 | Completed | Fochon Pharmaceuticals, Ltd. | 22 | 2019-06-25 | 2022-03-16 |
| Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c FCN-437c, Letrozole 2.5mg - Breast Neoplasms | Phase 1 / Phase 2 | Unknown | Ahon Pharmaceutical Co., Ltd. | 78 | 2019-02-14 | 2020-07-27 |
Breast Neoplasms (1) · Hepatic Insufficiency (1)
Ahon Pharmaceutical Co., Ltd. (4) · Fochon Pharmaceuticals, Ltd. (1)
China (4) · United States (1)
Amita Patmaik, MD (1) · Binghe Xu (1) · Haiyan Li, MD (1) · Xichun Hu, M.D. (1) · Yanhua Ding, PI (1)